دورية أكاديمية
أعرض في EDS

3-Hydroxy kynurenine treatment controls T. cruzi replication and the inflammatory pathology preventing the clinical symptoms of chronic Chagas disease.

التفاصيل البيبلوغرافية
العنوان: 3-Hydroxy kynurenine treatment controls T. cruzi replication and the inflammatory pathology preventing the clinical symptoms of chronic Chagas disease.
المؤلفون: Knubel CP; Departamento de Bioquímica Clínica, Facultad de Ciencias Químicas, Centro de Investigaciones en Bioquímica Clínica e Inmunología (CIBICI-CONICET), Universidad Nacional de Córdoba, Ciudad Universitaria, Córdoba, Argentina., Martínez FF, Acosta Rodríguez EV, Altamirano A, Rivarola HW, Diaz Luján C, Fretes RE, Cervi L, Motrán CC
المصدر: PloS one [PLoS One] 2011; Vol. 6 (10), pp. e26550. Date of Electronic Publication: 2011 Oct 19.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Chagas Disease/*prevention & control , Kynurenine/*analogs & derivatives , Trypanosoma cruzi/*drug effects , Trypanosoma cruzi/*physiology, Animals ; Chagas Disease/immunology ; Chagas Disease/parasitology ; Chronic Disease ; Female ; Inflammation/drug therapy ; Inflammation/immunology ; Inflammation/parasitology ; Interferon-gamma/metabolism ; Kynurenine/pharmacology ; Kynurenine/therapeutic use ; Mice ; Mice, Inbred BALB C ; Species Specificity ; T-Lymphocytes, Regulatory/drug effects ; T-Lymphocytes, Regulatory/immunology ; T-Lymphocytes, Regulatory/metabolism ; T-Lymphocytes, Regulatory/parasitology ; Trypanosoma cruzi/immunology ; Trypanosoma cruzi/pathogenicity
مستخلص: Background: 3-Hydroxy Kynurenine (3-HK) administration during the acute phase of Trypanosoma. cruzi infection decreases the parasitemia of lethally infected mice and improves their survival. However, due to the fact that the treatment with 3-HK is unable to eradicate the parasite, together with the known proapoptotic and immunoregulatory properties of 3-HK and their downstream catabolites, it is possible that the 3-HK treatment is effective during the acute phase of the infection by controlling the parasite replication, but at the same time suppressed the protective T cell response before pathogen clearance worsening the chronic phase of the infection. Therefore, in the present study, we investigated the effect of 3-HK treatment on the development of chronic Chagas' disease.
Principal Findings: In the present study, we treated mice infected with T. cruzi with 3-HK at day five post infection during 5 consecutive days and investigated the effect of this treatment on the development of chronic Chagas disease. Cardiac functional (electrocardiogram) and histopathological studies were done at 60 dpi. 3-HK treatment markedly reduced the incidence and the severity of the electrocardiogram alterations and the inflammatory infiltrates and fibrosis in heart and skeletal muscle. 3-HK treatment modulated the immune response at the acute phase of the infection impairing the Th1- and Th2-type specific response and inducing TGF-β-secreting cells promoting the emergence of regulatory T cells and long-term specific IFN-γ secreting cells. 3-HK in vitro induced regulatory phenotype in T cells from T. cruzi acutely infected mice.
Conclusions: Our results show that the early 3-HK treatment was effective in reducing the cardiac lesions as well as altering the pattern of the immune response in experimental Chagas' disease. Thus, we propose 3-HK as a novel therapeutic treatment able to control both the parasite replication and the inflammatory response.
References: Braz J Med Biol Res. 1986;19(3):379-88. (PMID: 3594003)
Eur Heart J. 2008 Nov;29(21):2587-91. (PMID: 18840880)
Proc Natl Acad Sci U S A. 1984 Feb;81(3):908-12. (PMID: 6422465)
Nucleic Acids Res. 1989 Aug 11;17(15):6408. (PMID: 2771657)
Clin Immunol. 1999 Apr;91(1):17-24. (PMID: 10219250)
J Exp Med. 1991 Sep 1;174(3):539-45. (PMID: 1908509)
J Immunol. 2010 Sep 15;185(6):3190-8. (PMID: 20720200)
Annu Rev Immunol. 2001;19:683-765. (PMID: 11244051)
Rev Inst Med Trop Sao Paulo. 1964 May-Jun;6:93-100. (PMID: 14177814)
Ann Intern Med. 2006 May 16;144(10):724-34. (PMID: 16702588)
Medicina (B Aires). 1999;59 Suppl 2:25-40. (PMID: 10668240)
Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):19961-6. (PMID: 21041655)
Annu Rev Microbiol. 1995;49:175-200. (PMID: 8561458)
Clin Immunol. 2000 Nov;97(2):89-94. (PMID: 11027448)
Infect Immun. 2011 May;79(5):2120-30. (PMID: 21357719)
Cell Death Differ. 2002 Oct;9(10):1069-77. (PMID: 12232795)
Muscle Nerve. 2000 Sep;23(9):1407-13. (PMID: 10951444)
Immunity. 2005 May;22(5):633-42. (PMID: 15894280)
Clin Exp Immunol. 2002 Jun;128(3):421-8. (PMID: 12067296)
Lancet Infect Dis. 2001 Sep;1(2):92-100. (PMID: 11871482)
Antimicrob Agents Chemother. 2007 Aug;51(8):2905-10. (PMID: 17526757)
Prog Cardiovasc Dis. 1964 Nov;7:199-225. (PMID: 14223289)
Mol Cell Biol. 1987 Nov;7(11):4065-74. (PMID: 3323886)
Immunity. 2009 May;30(5):626-35. (PMID: 19464985)
Nucleic Acids Res. 1992 May 25;20(10):2599. (PMID: 1598221)
J Immunol. 2010 May 15;184(10):5628-36. (PMID: 20393141)
Science. 2007 Aug 3;317(5838):627-9. (PMID: 17673654)
Acta Trop. 2007 Sep;103(3):195-200. (PMID: 17662227)
J Exp Med. 2002 Jun 3;195(11):1499-505. (PMID: 12045248)
Mem Inst Oswaldo Cruz. 1987 Jan-Mar;82(1):59-66. (PMID: 3507566)
Clin Exp Immunol. 2000 Mar;119(3):507-15. (PMID: 10691924)
J Immunol. 1993 Dec 15;151(12):7038-47. (PMID: 8258708)
Expert Rev Anti Infect Ther. 2007 Aug;5(4):717-26. (PMID: 17678432)
Microbes Infect. 2008 May;10(6):680-8. (PMID: 18485782)
J Immunol. 2002 Oct 15;169(8):4183-9. (PMID: 12370347)
Medicina (B Aires). 1981;41(1):35-9. (PMID: 7266356)
Trends Parasitol. 2005 Nov;21(11):513-6. (PMID: 16125464)
J Biol Chem. 1993 Mar 5;268(7):5077-84. (PMID: 8444884)
Rev Inst Med Trop Sao Paulo. 2008 Mar-Apr;50(2):67-74. (PMID: 18488083)
Gene. 2009 Dec 1;448(1):1-6. (PMID: 19699281)
Mem Inst Oswaldo Cruz. 1990 Oct-Dec;85(4):539-43. (PMID: 1726801)
J Exp Med. 1986 May 1;163(5):1037-50. (PMID: 2871125)
Infect Immun. 2007 Feb;75(2):861-9. (PMID: 17101658)
PLoS Med. 2007 Dec;4(12):e332. (PMID: 18162039)
J Immunol. 2006 Jun 1;176(11):6752-61. (PMID: 16709834)
J Immunol. 1999 May 15;162(10):6092-9. (PMID: 10229851)
Infect Immun. 2000 Jan;68(1):197-204. (PMID: 10603388)
Acta Trop. 2010 Jul-Aug;115(1-2):14-21. (PMID: 19932071)
Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10301-6. (PMID: 9294205)
FASEB J. 2010 Aug;24(8):2689-701. (PMID: 20233946)
Rev Inst Med Trop Sao Paulo. 1992 Sep-Oct;34(5):389-94. (PMID: 1342100)
Eur J Immunol. 2000 Nov;30(11):3181-9. (PMID: 11093133)
Microbes Infect. 2008 Jun;10(7):825-33. (PMID: 18538611)
Infect Immun. 2008 Jan;76(1):324-33. (PMID: 17967857)
Int J Parasitol. 2001 May 1;31(5-6):550-4. (PMID: 11334941)
Nat Med. 2008 May;14(5):542-50. (PMID: 18425131)
Nat Rev Immunol. 2004 Oct;4(10):762-74. (PMID: 15459668)
J Exp Med. 2002 Aug 19;196(4):447-57. (PMID: 12186837)
Exp Parasitol. 1998 Mar;88(3):223-30. (PMID: 9562426)
J Exp Med. 2003 Dec 15;198(12):1875-86. (PMID: 14676299)
Biochem Biophys Res Commun. 2005 Dec 9;338(1):20-4. (PMID: 16157293)
Cardiovasc Res. 2000 Jan 1;45(1):231-7. (PMID: 10728340)
Infect Immun. 1986 Aug;53(2):347-51. (PMID: 3089936)
Am Rev Respir Dis. 1979 Oct;120(4):893-9. (PMID: 92208)
Microbes Infect. 2004 Nov;6(14):1250-8. (PMID: 15555530)
J Infect Dis. 1999 Aug;180(2):480-6. (PMID: 10395865)
المشرفين على المادة: 27723548JL (3-hydroxykynurenine)
343-65-7 (Kynurenine)
82115-62-6 (Interferon-gamma)
تواريخ الأحداث: Date Created: 20111027 Date Completed: 20120224 Latest Revision: 20211020
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC3197528
DOI: 10.1371/journal.pone.0026550
PMID: 22028903
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0026550